PRER14A: Preliminary revised proxy soliciting materials

PRER14A：初步修订代理权征集材料

Moomoo AI 已提取核心信息

FOXO Technologies is seeking shareholder approval to allow full conversion of its Series A Preferred Stock into Class A Common Stock, potentially exceeding 20% of outstanding shares. This move aims to comply with NYSE American rules and fulfill requirements from a recent exchange agreement with Rennova Health.If approved, the proposal would remove current limitations on Series A Preferred Stock conversion and voting rights. It could significantly increase the number of Class A Common shares outstanding and potentially shift voting control to Series A Preferred holders. As of the record date, Rennova Health owns 21,000 Series A Preferred shares, which could represent a majority voting stake post-approval.The company warns that failure to obtain approval within 60 days would increase a related $1 million note to $2.5 million, potentially leading to default. Shareholders will vote on this proposal and a potential meeting adjournment at a special meeting to be held virtually in January 2025.

FOXO Technologies正在寻求股东批准，以允许将其A系列优先股完全转换为A类普通股，可能超过20%的流通股。这一举措旨在遵守纽交所美国的规章，并满足与Rennova Health最近签署的交易所协议的要求。如果获得批准，该提案将取消对A系列优先股转换和投票权的当前限制。这可能会显著增加流通的A类普通股数量，并可能将投票控制权转移给A系列优先股持有者。截至记录日期，Rennova Health拥有21,000股A系列优先股，这可能在批准后代表多数投票权。该公司警告称，如果未能在60天内获得批准，将会使相关的100万美元的票据增加到250万美元，这可能导致违约。股东将在2025年1月召开的特殊会议上对该提案及可能的会议休会进行投票，这次会议将以虚拟形式举行。

有用

没用

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

PRER14A: Preliminary revised proxy soliciting materials

PRER14A: Preliminary revised proxy soliciting materials

Moomoo AI 已提取核心信息

风险及免责提示

声明